No cure exists yet, but treatment can slow some types of dementia

There is no cure for dementia today. Once brain cells die, current medicine cannot replace them or reverse that damage. However, this does not mean nothing can be done. For some forms of dementia—particularly early Alzheimer's disease—newer medications can slow cognitive decline by months to a few years. Other treatments manage symptoms like memory loss, confusion, and behavioral changes, which can improve daily life even if they do not stop the disease itself.

The distinction matters: slowing decline is not the same as curing, but it can mean the difference between losing independence in two years versus four years. For other types of dementia, like vascular dementia or Lewy body dementia, treatment focuses on managing the underlying cause (like blood pressure or Parkinson's symptoms) and supporting the person through cognitive changes.

Key Takeaways

  • No medication reverses dementia damage, but some Alzheimer's drugs can slow memory loss by several months to a few years in early stages.
  • Lecanemab (Leqembi) and aducanumab (Aduhelm) target amyloid plaques in the brain; lecanemab has stronger evidence but requires regular infusions and carries a small risk of brain swelling.
  • Vascular dementia, Lewy body dementia, and frontotemporal dementia have no disease-modifying treatments; care focuses on managing symptoms and underlying conditions.
  • Lifestyle changes—exercise, cognitive activity, social engagement, sleep, and heart health—may slow decline and are recommended alongside any medication.

How Alzheimer's medications work and what they can do

The two medications that slow Alzheimer's decline work by targeting amyloid, a protein that builds up in the brains of people with Alzheimer's disease. Lecanemab (brand name Leqembi) was approved by the FDA in January 2023 and is given as an intravenous infusion every two weeks. In clinical trials, people taking lecanemab experienced a 27% slowing of cognitive decline over 18 months compared to placebo—roughly four to five months of delay in symptom progression.

Aducanumab (Aduhelm) was approved in 2021 but with significant controversy. It also targets amyloid, but the evidence that it slows cognitive decline is weaker than lecanemab's. Some insurance plans do not cover it, and many neurologists do not prescribe it. Both drugs require regular monitoring with MRI scans because they carry a small risk of amyloid-related imaging abnormalities (ARIA)—brain swelling or microhemorrhages that can cause headaches, confusion, or vision changes.

These medications work only in early stages of Alzheimer's disease—typically mild cognitive impairment or mild dementia—and only in people whose brain scans show amyloid buildup. They do not work for people with moderate or advanced dementia, and they do not restore lost memory or function.

Why other types of dementia have no disease-modifying treatments

Alzheimer's disease accounts for 60 to 80% of dementia cases, which is why research and drug development have focused there. Other forms of dementia have different underlying causes and have received less research funding and fewer treatment trials.

Vascular dementia, the second most common type, results from reduced blood flow to the brain due to stroke or small vessel disease. Treatment focuses on managing the cause: controlling blood pressure, taking antiplatelet medications like aspirin, and reducing stroke risk. These steps may prevent further decline but cannot reverse damage already done.

Lewy body dementia involves abnormal protein deposits in the brain and often includes Parkinson's-like symptoms, hallucinations, and sleep disturbances. There is no medication that targets Lewy bodies themselves. Treatment addresses individual symptoms—medications for movement problems, antipsychotics for hallucinations (used cautiously, as some can worsen Lewy body dementia), and sleep aids.

Frontotemporal dementia damages the front and side regions of the brain and typically strikes people in their 50s and 60s. No disease-modifying treatment exists. Care focuses on behavioral management, speech therapy, and support as the disease progresses.

What research is underway

Multiple drug candidates are in clinical trials, targeting different mechanisms. Some aim to reduce tau, another protein implicated in Alzheimer's and other dementias. Others target inflammation, neurodegeneration, or the buildup of other proteins. A few trials are testing combinations of drugs—for example, lecanemab plus an anti-tau medication—to see if attacking multiple pathways works better than one drug alone.

Research into blood tests that detect dementia earlier is advancing rapidly. Simpler, cheaper tests for amyloid, tau, and phosphorylated tau in blood plasma could identify people at risk years before symptoms appear, potentially opening a window for preventive treatment. However, these tests are not yet standard in clinical practice and are mainly used in research settings.

"Underway" does not mean "coming soon." Most drugs in trials fail. Even successful candidates typically take 5 to 10 years from trial completion to FDA approval and then to widespread availability.

Lifestyle changes that may slow decline

Evidence shows that certain behaviors are associated with slower cognitive decline, even in people with diagnosed dementia. Physical exercise—particularly aerobic activity like walking, swimming, or cycling—appears to be one of the most robust protective factors. Studies suggest 150 minutes of moderate activity per week may help preserve cognition.

Cognitive engagement through learning, puzzles, reading, or social games may also slow decline, though the evidence is less definitive than for exercise. Social connection and staying mentally active are linked to better cognitive outcomes. Sleep quality matters: poor sleep is associated with faster amyloid accumulation in the brain. Heart health—managing blood pressure, cholesterol, and diabetes—reduces vascular damage that compounds dementia.

These approaches are not cures and do not stop dementia, but they are recommended as part of any treatment plan. They also carry no serious side effects and benefit overall health regardless of dementia status.

The difference between slowing decline and halting it

When a medication slows cognitive decline by 27%, as lecanemab does, that means the rate of memory loss and confusion decreases—not that the person stops declining or returns to normal. Someone who would have lost significant function in 18 months might retain more independence for 24 months instead. The disease still progresses; it progresses more slowly.

This matters for planning. A few extra months or years of independence can mean staying in one's home longer, maintaining relationships more fully, or having time to arrange care. But it also means families should not expect medication to restore lost abilities or prevent eventual need for care.

For people in early stages of Alzheimer's disease, discussing lecanemab or other options with a neurologist or geriatrician is worth doing. The decision involves weighing the modest benefit against the commitment to infusions every two weeks and the small risk of brain swelling. For other types of dementia, the conversation focuses on symptom management and lifestyle support.

What "cure" might look like in the future

A true cure would need to either restore dead brain cells or prevent them from dying in the first place. Current research explores both directions, but neither is close to reality. Some scientists study whether stem cells could replace damaged neurons—still experimental in animals. Others investigate whether catching dementia at the preclinical stage (before symptoms appear) and treating aggressively might prevent symptoms from ever developing.

The most realistic near-term hope is earlier detection and earlier treatment. If blood tests can identify amyloid buildup 10 or 15 years before symptoms, and if drugs can slow that process enough, some people might never develop noticeable cognitive decline. That would not be a cure in the traditional sense, but it would be prevention—which, for many people, would be just as valuable.

Frequently Asked Questions

Can lecanemab stop my dementia from getting worse?

Lecanemab slows decline but does not stop it. In trials, people on the drug declined about 27% more slowly than those on placebo over 18 months. That translates to roughly four to five months of delay. The disease continues to progress; it just progresses more slowly.

What if I have already lost a lot of memory—can medication help me now?

Lecanemab and aducanumab only work in early stages of Alzheimer's disease. If you have moderate or advanced dementia, these medications are not recommended. Your doctor may focus on managing symptoms like confusion, sleep problems, or mood changes, and on supporting quality of life.

Is there anything that can prevent dementia if I do not have it yet?

No medication prevents dementia in people without symptoms. However, managing heart health, staying physically active, staying mentally engaged, sleeping well, and maintaining social connections are all associated with lower dementia risk. These are worth doing regardless, but they are not guarantees.

Why is there a cure for some diseases but not dementia?

Dementia involves death of brain cells, which the body cannot replace. Many infections or cancers can be cured because the underlying damage is reversible or the harmful agent can be eliminated. Brain cell death is permanent with current technology. Research aims to prevent that death or catch it early enough to intervene, but reversing it remains beyond current medicine.

How do I know if a new dementia treatment I hear about is real?

Real treatments are approved by the FDA (in the United States) or similar regulatory bodies in other countries, and they are prescribed by neurologists or geriatricians. Be cautious of claims that a supplement, diet, or unproven drug "cures" or "reverses" dementia. If you hear about a new option, ask your doctor whether it has completed clinical trials and whether it is appropriate for your stage and type of dementia.